Research Radar — 2026-08-22

Summary: CLEAR-ST models mRNA lateral diffusion in capture-based spatial transcriptomics as a graph-Laplacian forward contamination process with learnable diffusion parameters, inferring a latent clean expression field with a denoising autoencoder and selectable count likelihood. The authors report improved spatial-domain recovery, gene-level spatial autocorrelation, marker and pathway specificity, and cell-type deconvolution across Visium samples with varying contamination burden.

Why it matters: It makes a physically interpretable contamination model part of probabilistic inference rather than treating spatial halos as generic noise, offering a transferable way to improve atlas-scale tissue measurements.

Why for Yiru: Spatial omics correction directly affects the reliability of tissue mapping and downstream tumor-microenvironment analyses, especially when boundary-associated contamination can distort cell states and spatial relationships.

Summary: This work presents two approaches for scaling the Human Reference Atlas ecosystem: projecting data across biomedical reference-atlas systems and using millitomes to bulk-register tissue blocks into a reference organ. Both use the AMAP pipeline to align 3D mesh models through point-cloud registration; demonstrations span six atlas models and more than 300 tissue extraction sites across five organs.

Why it matters: Scalable registration across organs, assays, and coordinate systems is infrastructure for atlas-level biology, where manual sample alignment cannot keep pace with datasets and atlasing efforts.

Why for Yiru: Cross-atlas spatial alignment is relevant to building reference maps and digital-twin representations in which tissue measurements can be compared across specimens and biological contexts.

Summary: CaMeRe combines domain-invariant causal representation learning with bi-level meta-learning to predict patient-specific responses to drug combinations despite scarce patient-derived data and unobserved domain factors. The study reports multi-domain generalization across clinical and PDX datasets and applies the model to score 3,423 patients across 542,080 combinations, prioritizing candidates across 11 cancer types.

Why it matters: The framework targets the generalization gap between cancer-cell-line benchmarks and heterogeneous patient responses, while making broad prioritization claims that still require prospective response experiments.

Why for Yiru: Patient-specific combination modeling is a direct bridge between computational oncology, biomedical AI, and therapeutic design beyond cell-line-only evidence.

Summary: The study benchmarks docking protocols using experimental GPCR structures and Gaussian-accelerated molecular-dynamics ensembles across four Class A GPCRs, four docking programs, validated modulator libraries, and matched decoys. Ensemble topology determines whether minimum- or average-binding-energy reranking is useful; a consensus of both improves early hit diversity, while Boltz-2 shows limited sensitivity to the templates in this benchmark.

Why it matters: It shows why structure-based screening should benchmark conformational ensembles and reranking strategies rather than report a single favorable protocol.

Why for Yiru: The evaluation framework is a practical guide for structure-based drug discovery and for judging when learned affinity models complement, rather than replace, physics- and empirical-based docking.

Summary: NACraft is a training-free, programmatic framework that backpropagates through structure-model feedback to jointly optimize nucleic-acid sequence, binding, similarity, and anti-binding constraints. It supports de novo and similarity-guided RNA and DNA design; the authors report improved matched AlphaFold3 evaluation versus ODesign and in-silico target selectivity for EGFR over HER2.

Why it matters: It connects structure-model-in-the-loop generation to target-selective molecular design without task-specific training, but the evidence remains computational and needs wet-lab validation.

Why for Yiru: The sequence–structure–binding formulation is relevant to experimentally testable aptamer discovery and to broader biomedical-AI approaches for therapeutic molecular design.